b6c4399b-a4b6-4fcd-815c-554dc1a79ff7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.400
- WNT_BETA_CATENIN_SIGNALING+0.300
- MITOTIC_SPINDLE+0.200
- MYC_TARGETS_V1+0.200
- MYC_TARGETS_V2+0.200
- MYOGENESIS+0.200
- PANCREAS_BETA_CELLS+0.200
- APICAL_JUNCTION+0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.100
- HEDGEHOG_SIGNALING+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- IL6_JAK_STAT3_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- CHOLESTEROL_HOMEOSTASIS-0.300
- COMPLEMENT-0.300
- IL2_STAT5_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20ed86b0-2e3d-44ec-88cd-eac5486fe15c | — | — | 0.822 |
| 2 | ca7940e6-af7e-44fd-a6fc-5d86dc1d86c4 | — | — | 0.818 |
| 3 | TCGA-AC-A5XU-01A-11R-A28M-07 | — | B | 0.810 |
| 4 | TCGA-NC-A5HP-01A-11R-A26W-07 | — | cohortSQ1 | 0.800 |
| 5 | 9a38d0dc-6b2c-439d-b10e-efd0f1cba209 | — | — | 0.795 |
| 6 | 7478db87-0751-4771-941f-9fccdf01853d | — | — | 0.793 |
| 7 | ea89121f-2c74-433d-8047-898dc963bf35 | — | — | 0.792 |
| 8 | TCGA-63-A5MW-01A-11R-A26W-07 | — | cohortMD1 | 0.789 |
| 9 | 4ce20929-7d04-4c4b-9e3c-de22d237f254 | — | — | 0.786 |
| 10 | SAMN03290896 | — | — | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |